ERC1671

Phase 2Small molecule

EEpitopoietic Research Corporation

ERC1671 is one of 79 small molecule programs targeting Malignant Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant GliomaNot yet recruiting

Glioblastoma MultiformeActive, not recruiting

Malignant GliomaPhase 2

Not yet recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Glioblastoma Multiforme

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

82 2

Avastin

Roche

Phase 3

27 3

Bayer Aspirin

Keppra

Cialis

Depakote

Stivarga

Tagrisso

Talzenna

Namenda

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma Multiforme1 trial

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Active, not recruiting·EEpitopoietic Research Corporation·Phase 2·NCT01903330·84 enrolled

Malignant Glioma1 trial

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Not yet recruiting·EEpitopoietic Research Corporation·Phase 2·NCT05366062·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ERC1671. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ERC1671 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ERC1671. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Epitopoietic Research Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEpitopoietic Research Corporation

ERC1671

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma Multiforme1 trial

Malignant Glioma1 trial

References

Drug Info

Quick Facts

Related News